The World Health Organization classifies meningiomas into three grades that reflect how aggressively the tumor tends to behave. Grade 1 meningiomas are slow-growing and account for roughly 80 percent of cases, grade 2 tumors carry a higher risk of recurrence, and grade 3 meningiomas are the rarest and most aggressive. The grading system has evolved considerably over the past decade, and the most recent 2021 WHO edition now folds molecular findings into what was once a purely microscopic assessment, meaning two tumors that look identical under a microscope can receive different grades based on their genetic makeup.
What Each Grade Means in Practice
A grade 1 meningioma is sometimes called “benign,” though that label can be misleading. These tumors grow slowly, and after complete surgical removal many patients do well for years. But they are not without risk. Research shows that grade 1 meningiomas still recur at a meaningful rate after surgery, and features like a high cell-proliferation index can independently predict which ones are more likely to come back.1PubMed. Resected WHO grade I meningioma and predictors of local control Factors such as tumor location in the posterior fossa and the degree of nuclear atypia also raise the odds of recurrence, even within this lowest grade.2PubMed Central. WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index
Grade 2, often called “atypical,” sits in the middle. Under the 2021 WHO classification, a meningioma earns a grade 2 designation if it has one major feature, such as 4 to 19 mitotic figures per 10 high-power fields or evidence of brain invasion, or at least three of five specified minor features including small cells with a high nuclear-to-cytoplasmic ratio, prominent nucleoli, sheet-like growth, and foci of necrosis.3PubMed Central. Atypical meningiomas compared to other WHO Grade 2 meningiomas: Histological features and prognosis One study of atypical meningiomas reported a median overall survival of about 60 months and a median progression-free survival of roughly 53 months, though outcomes vary widely depending on surgical completeness and other individual factors.4PubMed Central. Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
Grade 3, or anaplastic, meningiomas are rare and aggressive. They can arise on their own or evolve from a previously lower-grade tumor. In a retrospective study of 48 patients with grade 3 meningiomas, the median progression-free survival was roughly 14 months and the median overall survival was about 57 months.5PubMed Central. Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome Three-quarters of those patients underwent gross total resection, and about two-thirds received radiation afterward, which gives some sense of how intensively these tumors are treated.
Brain Invasion and Why It Changed the Grading Landscape
One of the most consequential changes in recent WHO editions involved brain invasion. Before 2016, a meningioma that pushed into brain tissue could still be classified as grade 1 if it lacked other atypical features. The 2016 classification made brain invasion a standalone criterion for upgrading a tumor to grade 2.6PubMed. Impact on natural history of atypical meningioma after changes in 2016 edition of the world health organization (WHO) classification of central nervous system tumors: a literature review The 2021 edition retained that rule.
This shift was not merely bureaucratic. Studies have confirmed that brain invasion independently raises the risk of recurrence. In one large analysis, meningiomas with brain invasion had roughly double the hazard of relapse compared to those without it in the atypical subcohort.7Journal of Neurosurgery. Is brain invasion sufficient as a stand-alone criterion for grading atypical meningioma? Other researchers found that meningiomas reclassified as grade 2 solely because of brain invasion had a similar median progression-free survival to those that met other atypical criteria, reinforcing that brain invasion on its own really does signal a more worrisome tumor.8PubMed. Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases
Molecular Markers Now Influence the Grade
The 2021 WHO classification introduced something genuinely new: for the first time, specific genetic alterations can bump a meningioma to grade 3 regardless of what the tumor looks like under a microscope. Two molecular findings now qualify as standalone criteria for anaplastic grading: TERT promoter mutations and homozygous deletion of the CDKN2A/B gene.9Neuro-Oncology Advances. Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status
TERT promoter mutations have drawn particular attention because of how powerfully they predict poor outcomes. In one study, patients whose meningiomas carried a TERT promoter mutation had a median time to progression of just 10 months, compared with roughly 179 months for those without the mutation.10PubMed Central. TERT Promoter Mutations and Risk of Recurrence in Meningioma Another analysis found that TERT promoter mutations were associated with roughly half the overall survival compared to wild-type tumors, and that this genetic change outperformed both patient age and WHO grade as an independent predictor of death.11Neuro-Oncology. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma TERT promoter mutations also appear to play a specific role in malignant progression: they were found in about 28 percent of meningiomas that transformed from a lower grade to a higher one, compared to almost none among tumors that recurred without upgrading.12PubMed Central. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression
What this means for you practically is that two patients with grade 2 meningiomas that look identical under the microscope may face very different futures depending on whether one of them carries a TERT promoter mutation. The molecular layer does not replace histological grading; it adds another dimension. Not every center routinely tests for these markers yet, but the trend is clearly moving toward broader molecular profiling.
Why Pathologists Sometimes Disagree on the Grade
One of the underappreciated realities of meningioma grading is that it involves a surprising degree of subjectivity. A multi-institutional trial found that agreement was highest for clear-cut features like brain invasion and very high mitotic counts, but was considerably lower for subtler criteria like sheeting patterns and small cells.13PubMed Central. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539 A separate study specifically examining atypical meningioma diagnosis found that four observers agreed on whether a tumor qualified as atypical only about 54 to 60 percent of the time. Agreement improved to roughly 63 to 74 percent when only two experienced neuropathologists reviewed the slides, but even that leaves meaningful room for disagreement.14PubMed Central. The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment
Mitotic counting, one of the most important grade 2 criteria, is a particular pain point. When pathologists used a more thorough scanning method, the number of cases classified as grade 2 jumped dramatically, from as few as 4-6 cases to 23-27 cases in the same cohort.15PubMed. Interobserver Variability in Mitotic Count for Meningioma Grading: How Can We Reduce It? The takeaway for patients is that a grade assignment is not always as clear-cut as it seems on paper, and a second opinion from a specialized neuropathologist can occasionally change the picture.
What Imaging Can and Cannot Tell You Before Surgery
Definitive grading requires tissue under a microscope, but imaging does offer some clues. A systematic review of CT and MRI features found that an irregular tumor-brain interface was the single most accurate imaging sign for identifying higher-grade disease, with roughly 80 percent accuracy. Cystic changes had the highest specificity, meaning if you see them, the tumor is more likely to be aggressive, while mass effect (the tumor pushing surrounding structures aside) was the most sensitive marker.16PubMed Central. Meningioma grading via diagnostic imaging: A systematic review and meta-analysis
Tumor volume stands out as a surprisingly strong pre-operative predictor. One study found it was the most robust single imaging indicator of higher-grade disease, even after accounting for surrounding brain swelling. Additional features like tumor necrosis on imaging, significant surrounding edema, and location along the falx or brain convexity all leaned toward atypical pathology in individual analyses.17PubMed. Differentiating meningioma grade by imaging features on magnetic resonance imaging None of these imaging signs are definitive enough to replace biopsy, but they help surgeons and neuro-oncologists plan the approach and set expectations.
How Tumor Location Connects to Genetics
Where a meningioma sits in the skull often correlates with its underlying genetic driver. A landmark genomic study found that meningiomas without NF2 mutations, instead carrying mutations in genes like TRAF7, KLF4, AKT1, and SMO, were almost always benign, chromosomally stable, and arose from the medial skull base. Meningiomas with NF2 mutations or chromosome 22 loss, by contrast, were more likely to be atypical, showed genomic instability, and tended to arise over the cerebral and cerebellar hemispheres.18PubMed Central. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO More recent immunohistochemical work has confirmed that skull base and non-skull base meningiomas differ significantly in the expression of key proteins including NF2 and TRAF7.19Journal of Health Science and Medical Research. Expression of NF2, TRAF7, PI3KCA, and PGR in Skull Base vs Non- Skull Base Meningiomas: A Quantitative Cross-Sectional Study
This matters because it suggests that meningioma is not one disease with three severity levels but rather a family of molecularly distinct tumors that happen to share a tissue of origin. A skull base meningioma driven by an AKT1 mutation is a biologically different entity from a convexity meningioma driven by NF2 loss, and the two behave differently even if they receive the same WHO grade.
How Grading Shapes Treatment Decisions
For grade 1 meningiomas, surgery is the primary treatment, and if the surgeon achieves a complete removal, many patients are simply monitored with periodic imaging. Radiation therapy is generally reserved for tumors that cannot be fully resected or that recur.
Grade 2 meningiomas present a more complicated decision. Adjuvant radiation is currently recommended after subtotal resection, but whether to add radiation after a complete resection remains genuinely controversial. Most studies suggest radiation improves progression-free survival, but the evidence for an overall survival benefit after gross total resection is thin and comes largely from retrospective data.20PubMed Central. Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues A systematic review concluded that close radiological and clinical follow-up is a reasonable option for completely resected grade 2 tumors, acknowledging the uncertainty.21PubMed. Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review
Grade 3 meningiomas almost always receive radiation after surgery. Beyond surgery and radiation, treatment options for recurrent or progressive higher-grade meningiomas have historically been limited. That picture is beginning to change as researchers explore targeted therapies directed at specific pathways, including inhibitors of angiogenesis, mTOR, CDK4/6, and FAK, as well as immune checkpoint inhibitors. Early-phase trials have shown signs of activity, and some patients have achieved prolonged disease control, though these remain investigational.22PubMed. Emerging targeted therapies in meningiomas
DNA Methylation May Outperform Traditional Grading
Perhaps the most interesting development on the horizon is methylation-based profiling. A research team developed a predictor based on DNA methylation patterns and found it outperformed the WHO grade-based system in predicting five-year recurrence-free survival. The methylation predictor remained independently associated with recurrence even after adjusting for histological grade, extent of resection, and chromosomal copy number changes.23PubMed Central. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
A prospective multicenter validation study recently confirmed and modestly improved upon those results, with the next-generation methylation predictor significantly outperforming the 2021 WHO grade system while using far fewer probes than the original model.24Neuro-Oncology. Validation and next-generation update of a DNA methylation–based recurrence predictor for meningioma: A multicenter prospective study If this approach becomes clinically available, it could help resolve the gray zone that currently vexes treatment decisions for grade 2 tumors. A patient with a grade 2 meningioma but a favorable methylation profile might be safely monitored, while one with an unfavorable profile might benefit from early radiation.
Quality of Life After a Meningioma Diagnosis
Grades are not just clinical abstractions. They have a real relationship to how patients feel. Systematic reviews have found that even patients with minimally symptomatic meningiomas report meaningfully impaired quality of life compared to healthy controls, across physical, cognitive, and psychosocial domains. Larger tumor size, higher histological grade, and tumor recurrence are all associated with worse quality-of-life scores.25Neuro-Oncology. Impaired health-related quality of life in meningioma patients—a systematic review Treatment of symptomatic meningiomas generally improves quality of life, cognitive function, and seizure control, but scores often remain depressed compared to the general population even after successful treatment.26PubMed Central. Health-related quality of life in meningioma
For grade 2 and 3 tumors specifically, the evidence is mixed. Some studies report reduced quality of life compared to grade 1 patients, while others find no significant difference after adjustment. Psychological domains, including anxiety and depression, appear to be reduced in most studies regardless of grade, and in the two studies that focused exclusively on grade 2 and 3 patients, psychological impairment stood out.27Neuro-Oncology. HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES IN CNS WHO GRADE 2 AND 3 MENINGIOMA: A SYSTEMATIC REVIEW The ongoing surveillance schedule, the uncertainty about recurrence, and the side effects of any radiation all contribute to a psychological burden that exists even when the tumor itself is controlled.
Pediatric Meningiomas Are Biologically Different
Though meningiomas are overwhelmingly an adult disease, they do occur in children. The grade distribution in pediatric cases is roughly similar to adults, with most tumors being grade 1.28PubMed Central. Pediatric meningiomas: A literature review and diagnostic update But comprehensive molecular analysis has revealed that pediatric meningiomas are substantially different from adult tumors in terms of histological subtype distribution, methylation profiles, and the specific mutations driving the tumor.29PubMed Central. Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas This means the adult-derived WHO grading framework may not predict outcomes for a child’s meningioma with the same reliability it offers for adults. It remains an active area of investigation.
Radiation-Induced Meningiomas and Their Grade Distribution
People who received cranial radiation earlier in life, whether for a childhood cancer, tinea capitis treatment, or another reason, face an elevated risk of developing a meningioma later. A large meta-analysis of over 900 radiation-induced meningiomas found that the grade distribution depends on the type of prior radiation. Among patients who had previously received cranial radiotherapy for cancer, about 31 percent of tumors were grade 1, roughly 13 percent were grade 2, and about 2.5 percent were grade 3. In contrast, those who had received radiation for tinea capitis had a higher proportion of grade 1 tumors, about 56 percent, with grade 2 and 3 making up smaller shares.30PubMed Central. Radiation-induced meningiomas: A systematic review and meta-analysis of 927 meningiomas The notably lower rate of grade 1 tumors in the cranial radiotherapy group compared to the general meningioma population suggests that radiation-induced meningiomas may lean toward more aggressive behavior.
Liquid Biopsy and the Future of Monitoring
One of the practical frustrations of meningioma management is that monitoring depends on periodic MRI scans, and by the time a scan detects regrowth, the recurrence is already established. Researchers are exploring whether blood-based tests, sometimes called liquid biopsies, could detect tumor-related signals earlier. A study examining circulating tumor DNA, microRNAs, and cytokines in meningioma patients found that detecting tumor DNA in blood was feasible, but matching plasma findings to known tumor mutations proved difficult. Only one patient in the study had a paired identification of the same mutation in both the blood and the tumor tissue.31PubMed Central. Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients The technology is promising in concept but far from clinical readiness. Meningiomas shed relatively little DNA into the bloodstream compared to many other cancers, and the sensitivity of current assays has not caught up.
The evolution of meningioma classification from purely microscopic assessment through the addition of brain invasion criteria and now molecular markers reflects a broader shift in neuro-oncology toward treating the biology of the tumor, not just its appearance.32PubMed Central. The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care For patients, the practical implication is that a WHO grade is an important starting point but not the full story. Molecular testing, methylation profiling, imaging characteristics, and surgical factors all layer onto that grade to shape the real-world prognosis and treatment plan.